The Pathology Core Facility (PCF) is a centralized, comprehensive facility that provides professional expertise in pathology and human tissue-based studies and is specifically dedicated to the needs ofthe Cancer Center research community. The PCF has three main components: research histology, specimen procurement and protocol review. The research histology is composed of three units: routine histology, immunohistochemistry and molecular testing. This includes processing of fixed and frozen tissues, construction of hypothesis driven tissue microarrays, newly improved methods for TMA mapping and creation, sophisticated processes for the extraction of analytes such as RNA and DNA from samples, matched to end-point assay techniques. The research histology section also designs and validates the analytical assays, which include antibody selection and optimization for immunohistochemistry, a newly incorporated in situ hybridization for RNA and DNA with chromogenic and fluorescent detection. Adjoining to the research histology is microscopy, which provides pathologic verification of diagnoses, and quantitative interpretation of results, based on microscopic evaluation, including a new high-throughput digital slide scanner. An annotation and scribing software (Collibio?) allows for distant review, retention of data with image, and conferencing. The biobanking component ofthe PCF has two main functions: human tissue procurement, and quality assurance and protection of research subjects. The tissue procurement section serves to obtain, process, store and distribute characterized neoplastic and benign human tissue. Specimens are not only procured for specific protocols and laboratory projects, but also there is an organized systematic effort for generalized procurement and storage for short and long-term cancer research. PCF maintains a universal IRB consent for procurement of all specimen types. As a member of ISBER and NCI Group Banking Committee, the PCF uses new information, ideas, technology, and regulations in further developing a non-renewable high quality biospecimens resource to meet all aspects of cancer research. Lastly, the PCF reviews all clinical protocols which involve human tissue specimens. The PCF is CAP-accredited, CLIA high-complexity certified, and has the capability to serve integral marker studies, which require biomarker-based treatment arm assignment. The PCF staff are members of institutional review committees, and in this manner provide input and oversight ofthe clinical trial protocol design, and the specifics of tissue release of retrospective specimens. These activities allow for incorporation of pathology-specific competencies into the design and conduct of translational studies, and integrate the PCF into multidisciplinary teams that serves the entire Cancer Center research community. In addition, the PCF also runs the NCI funded ECOG-ACRIN Pathology Coordinating Office - Reference Laboratory, which serves as the centralized center for processing and distribution of biospecimens obtained from patients enrolled in ECOG and intergroup clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA060553-20
Application #
8761071
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$255,142
Indirect Cost
$91,528
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Gopal, Satish; Achenbach, Chad J; Yanik, Elizabeth L et al. (2014) Moving forward in HIV-associated cancer. J Clin Oncol 32:876-80

Showing the most recent 10 out of 316 publications